ALGS
Aligos Therapeutics Inc
NASDAQ: ALGS · HEALTHCARE · BIOTECHNOLOGY
$5.99
+0.34% today
Updated 2026-04-30
Market cap
$39.60M
P/E ratio
—
P/S ratio
18.12x
EPS (TTM)
$-2.45
Dividend yield
—
52W range
$4 – $14
Volume
0.2M
WallStSmart proprietary scores
27
out of 100
Grade: F
Strong Sell
Investment rating
2.7
Growth
F7.0
Quality
B+2.5
Profitability
F4.0
Valuation
C4/9
Piotroski F-Score
Moderate
-15.8
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →200 stocks currently score above 75
Price targets
Analyst target
$65.80
+998.50%
12-Month target
—
—
Intrinsic (DCF)
$4.18
Margin of safety
-78.47%
1 Strong Buy4 Buy0 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Debt/equity 0.08x — low leverage
Risks
- Altman Z -15.76 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-21.84M
- Revenue declining -73.10% QoQ
- 78.47% above intrinsic value
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $13.91M | $15.53M | $3.94M | $2.19M | $2.19M |
| Net income | $-96.05M | $-87.68M | $-131.21M | $-24.19M | $-19.88M |
| EPS | — | — | — | — | $-2.45 |
| Free cash flow | $-80.33M | $-79.02M | $-80.87M | $-82.94M | $-21.84M |
| Profit margin | -690.63% | -564.61% | -3,326.01% | -1,106.72% | — |
Peer comparison
Smart narrative
Aligos Therapeutics Inc trades at $5.99. Our Smart Value Score of 27/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of -15.76, it sits in the distress. TTM revenue stands at $2.19M. Our DCF model estimates intrinsic value at $4.18.
Frequently asked questions
What is Aligos Therapeutics Inc's stock price?
Aligos Therapeutics Inc (ALGS) trades at $5.99.
Is Aligos Therapeutics Inc overvalued?
Smart Value Score 27/100 (Grade F, Strong Sell). DCF value $4.18.
What is the price target of Aligos Therapeutics Inc (ALGS)?
The analyst target price is $65.80, representing +998.5% upside from the current price of $5.99.
What is the intrinsic value of Aligos Therapeutics Inc (ALGS)?
Based on our DCF model, intrinsic value is $4.18, a -78.5% margin of safety versus $5.99.
What is Aligos Therapeutics Inc's revenue?
TTM revenue is $2.19M.
Piotroski F-Score?
4/9 — moderate financial health.
Altman Z-Score?
-15.76 — distress.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio18.12x
ROE-196.90%
Beta2.62
50D MA$7.18
200D MA$8.66
Shares out0.01B
Float0.00B
Short ratio—
Avg volume0.2M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—